media – Page 618 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Doctolib raises another $42 million for its medical care scheduling service

French startup Doctolib is raising money for the second time in the past twelve months. The company is building a sort of Salesforce for the healthcare industry with a big emphasis on bookings. Doctolib just raised $42 million (€35 million) from Eurazeo and existing investor Bpifrance.
- Source: Technologythrill
- 465
- November 29, 2017
Doctolib Market Views Series
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis

Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS).
- Source: businesswire
- 520
- November 29, 2017
ALKS 8700 Biogen Market Views
Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority

Review Designation of Mogamulizumab’s Biologics License Application
- Source: drugdu
- 494
- November 29, 2017
Biologics License Application FDA New Approvals
Do You Really Need To Stop Drinking On Antibiotics?

First, it's important to remember why you’re on antibiotics to begin with: You feel awful and, with some help from your prescription, your body is working to fight off a nasty bacterial infection. (Antibiotics cannot treat anything viral, like a flu.)
- Source: womenshealthmag
- 519
- November 29, 2017
antibiotics Researches
Radiotherapy-resistant tumors could be defeated with experimental drugs

It may be possible to use drugs that are already in development to overcome radiotherapy resistance in tumors, which is often a major barrier to the successful treatment of many cancers.
- Source: medicalnewstoday
- 550
- November 28, 2017
cancer radiotherapy Researches tumor
Are Antipsychotics Used Appropriately for Managing Dementia?

A study reviews data on the indications for use of antipsychotics in elderly patients with dementia across four clinical settings in Canada.
- Source: medicalnewsbulletin
- 536
- November 28, 2017
antipsychotics Dementia Researches
Zika Virus Kills Brain Cancer Stem Cells MEDICINE & HEALTH

While Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective treatment for glioblastoma, a deadly form of brain cancer. New research from Washington University School of Medicine in St. Louis and the University of California San Diego School of Medicine shows that the virus kills brain cancer stem cells, the kind of cells most resistant to standard treatments.
- Source: scienmag
- 580
- November 28, 2017
brain cancer glioblastoma Researches
Bay Area’s Medeor Therapeutics Bags $57M

Medeor Therapeutics announced it had closed on an oversubscribed Series B financing worth $57 million. The round was led by RA Capital Management. New investors included Sofinnova Ventures and 6 Dimensions Capital. They were joined by existing investors Vivo Capital and WuXi Healthcare Ventures.
- Source: Biospace
- 626
- November 28, 2017
cellular immunotherapies Market Views Series
Medical Products for Human Use

New technologies, therapies and medicines are emerging; this includes regenerative medicine, more personalised treatments, as well as the development of nanomedicines. The Commission is committed to monitoring scientific progress and to constantly review Community legislation in the light of new developments so as to make safe, novel treatments available to patients as early as possible.
- Source: ec.europa.eu
- 643
- November 28, 2017
nanomedicine polices regenerative medicine
Prometic Reports Positive Interim Clinical Data From Ongoing Intravenous Immunoglobulin Pivotal Phase III Trial

Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced positive interim six-month clinical data from its ongoing pivotal IVIG Phase 3 clinical trial in patients suffering from primary immunodeficiencies (PID) following review of the data by the Data Safety Monitoring Board (DSMB), which confirmed no significant safety issues and that efficacy appeared to be comparable to existing commercial IVIG products.
- Source: Prometic
- 507
- November 28, 2017
Clinical Trials IVIG PID

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.